Printer Friendly

Comparison of Caffeine versus Theophylline for apnea of prematurity.

Byline: Arif Zulqarnain, Muddasser Hussain, Khalid Munir Suleri and Zafar Ali Ch.

KEYWORDS: Caffeine, Theophylline, Apnea, Infants, Prematurity.

INTRODUCTION

In the past, there have been reports of applicability of methylxanthines and theophylline being used for the cure of episodic apnea in premature infants till they complete a post-conceptional age of 34-35 weeks.1 As demonstrated by a literature review designed for the objective of prophylaxis or treatment of apnea of prematurity, some documentation regarding the use of theophylline or caffeine depicting some degree of altercation regarding the dosage regime2, the appropriate concentration of serum methylxanthine, the compulsion for drug monitoring, and the outcome of drug usage,3 is still present.

A variety of studies have recommended a vast range of appropriate dosage regimen for caffeine (loading dose 3-40 mg/kg; maintenance dose 1.5- 15 mg/kg/day caffeine-base). whereas the Safer reported dose as less than 80mg/L having 2-6 caffeine concentration, while 4 up to 93 mg/L is better tolerated and as less as 3-4 mg/L abates the apnea and accentuates the respiratory effort.4 Nonetheless, a high-loading dose of 25 mg/kg of caffeine, decrease the blood supply to cerebral and the intestinal areas in the pre-term neonates. It may result in neurologic complications akin to the transformation of astrocytogenesis which occurs after the postnatal exposure to low dose caffeine (less than 50 mg).5 Conversely, the degree of survival has been claimed to improve in apnea of prematurity (AOP) in very low birth weight (VLBW) infants upon the use of caffeine at optimal doses for the treatment.6 It does not bring about any neurologic incompetency at 18-21 months.

It also decreases the likelihood of bronchopul monary dysplasia. Adding further, the latest researches have established that if caffeine is used in standard doses (doses used in study), it does not necessitate the need for monitoring.7

Loading dose 4.4-9 mg/kg and maintenance dose 2-12 mg/kg/day have been used accomplishing plasma levels between 4-24 mg/L whereas levels as little as 1.3mg/dL are observed as efficacious.8 A strong recommendation of therapeutic monitoring has been made in order to get the therapeutic levels of theophylline between 5-12 mg/L. The prophylaxis of AOP by theophylline has not been successfully supported by previous studies. Neither of them has proclaimed the use of theophylline. Further research is recommended to determine the prophylaxis by methylxanthines. Being the inhibitors of adenosine receptors, both methylxanthines demonstrate the adverse effects and might as well poorly influence the pre-term development of the brain.9

Presently, it can be fairly described that caffeine is the approved methylxanthine in order to treat AOP in most of the neonatal care facilities. This observation is based on a limited amount of data.10 As such, the objective of the study was to make a comparison between theophylline and caffeine when used in standard doses in order to treat and prevent AOP in pre-term neonates to determine any differences in regards to (i) the episodes of apnea (ii) the relationship between serum concentration of methylxanthines and related apneic episodes and (iii) the requirement for monitoring of drug.

METHODS

A randomized control study was conducted in Department of Pediatrics Medicine Govt. Khawaja Muhammad Safdar Medical College and Govt. Allama Iqbal Memorial Teaching Hospital, Sialkot over duration of one year August 2017 to August 2018 after approval from the ethics committee was obtained. An informed consent in the form of written document was also taken from the parents of each infant participating in the study.

The eligible candidates for the study included those infants born before 33 weeks of gestation. They were breathing spontaneously and were predicted to be administered with methylxanthine either therapeutically or prophylactically for AOP. Discontinuance of breathing for more than 20s or short but correlated with hypoxia (oxygen saturation <85%) or bradycardia (heart rate <100 bpm); was defined as Apnea.

After experiencing three episodes of apnea, infant was started upon the treatment, necessitating intense interventions with 24 hours, while if attacks of apnea were less than three in number, the infant was put on prophylaxis. All the participants were well maintained clinically, apart from their apneic events. Patients were divided into two groups (group A and B) by lottery method.

The elimination standard included congenital disorders, neuromuscular anomalies, perinatal asphyxia, IC hemorrhage, metabolic disorders, anemia, disseminated infection, severe GERD and previous introduction of methylxanthine.

A modification design that is computer propagated was utilized to describe the infants into the treatment groups Sigma Stat statistical package, Version 23. An authorized clinical pharmacist, un-involved with the research or the clinical management of infants otherwise, enforced the treatment assignment. The clinicians were not blinded due to use of different drug dosages and timings for blood sample.

After randomization, the infants were subjected to the use of theophylline (group-1) or caffeine (group 2) for the treatment of apneic episodes. The following optimal regime for the administration of theophylline was used. Theophylline (given intravenously in 30 minutes) loading doses 4.8 mg/kg (related to 6 mg/kg) and maintenance dose 2 mg/kg (up to 2.8 mg/kg) every 12 hour (related to 2.5-3.5 mg/kg) - caffeine citrate: loading dose 20 mg/kg (complementary to 10 mg/kg caffeine-base) given IV in 30 minutes and maintenance doses 5 mg/kg (up to 10 mg/kg) (consonant to 2.5-5 mg/kg caffeine-base) given IV in 30 minutes. (2.5-5 mg/kg caffeine-base) given once daily IV in 10 minutes. The therapy was carried on as far as the gestational age of 34 weeks or maybe shorter in case of transfer of infants to another hospital by sending physician with that child.

Blood sample of infants were withdrawn in order to determine the concentrations of caffeine and theophylline, as well as to determine the levels of caffeine in those candidates receiving caffeine citrate at the mentioned times of two hours after consummation of administration of loading dose and fifteen minutes prior to the introduction of maintenance doses on day three and day seven of therapy and every seven days thenceforth. Serum concentration of 5-12 mg/L was maintained and the dose of caffeine was modified upon signs of toxicity observed at the levels more than 50mg/L.

The observation of the infants was done before and during the methylxanthine treatment, with the help of a cardio respiratory monitor and a pulse oximeter. The other vitals recorded were heart rate, respiratory rate and oxygen saturation and the analysis of measurements was done by the administering physician in order to determine the episodes of apnea and it was examined by one of the authors after every 24 hours. The blinding was done for the author and the final data analyst for the prevention of bias. The alarm for tachycardia and bradycardia were set at 200 and 100 beats/minute respectively, while the oxygen saturation alarm was being set at 85%. At the bedside, a sheet for apnea nursing was maintained for all the infants upon whom the nurses were supposed to record the optimal intercessions for the corresponding events of apnea. The statistics of apnea did not alter the analysis of physician, done by nurses, to prevent under-estimation.

Table-I: Demographic Characteristics among the study groups.

Characteristics###Theophylline###Caffeine###P value

###(n=50)###(n=50)

Gestational###30.44+-1.63###32.02+-1.31###<0.001

###Age(weeks)

Supplemental O2###24%(n=12)###26%(n=13)###0.817

Nasal CPAP###14%(n=7)###10%(n=5)###0.538

IVH grade I###6%(n=3)###12%(n=6)###0.295

Table-II: Serum concentrations in infants receiving caffeine and theophylline for apnea of prematurity.

Characteristics###Theophylline###Caffeine###P value

###(n=50)(n=50)

###Mean concentration

Day 3###6.62+-1.69###13.29+-2.50###<0.001

Day 7###7.28+-1.03###11.15+-2.87###<0.001

Day 14###6.93+-0.93###12.19+-2.82###<0.001

Day 21###6.44+-1.21###11.06+-2.07###<0.001

RESULTS

One hundred (n=100) infants were enrolled in this study. This study was further divided into two equal groups i.e. 50% (n=50) in each, treated with Theophylline and Caffeine respectively. The mean gestational age of Theophylline group was 30.44+-1.63 weeks. Mean gestational age of Caffeine group was 32.02+-1.31 weeks. Supplemental O2 was observed as 24% (n=12) and 26% (n=13) for Theophylline group and Caffeine group respectively. Nasal CPAP was noted in 14% (n=7) and 10% (n=5) infants, for Theophylline group and Caffeine group respectively. While, IVH Grade-I was observed in 6% (n=3) and 12% (n=6) infants, for Theophylline group and Caffeine group respectively. The difference was statistically insignificant, except gestational age (p=0.000). (Table-I).

The mean concentration at day 3, 7, 14 and 21 of Theophylline group was 6.62+-1.69, 7.28+-1.03, 6.93+-0.93 and 6.44+-1.21 respectively. The mean concentration at day 3, 7, 14 and 21 of Caffeine group was 13.29+-2.50, 11.15+-2.87, 12.19+-2.82 and 11.06+-2.07 respectively. The differences were statistically significant (p<0.005), according to student t test. (Table-II).

Mean apnea events/day in neonates administrated by theophylline was 1+-0.1, 2+-0.12, 2+-1.1, 1+-0.10 and 2+-0.12 for 0, 1-3, 4-7, 8-14 and 15-21 days respectively. While, the mean apnea events/day in neonates administrated by Caffeine was 2+-0.3, 1+-0.22, 2+-1.5, 1+-0.13 and 2+-0.14 for 0, 1-3, 4-7, 8-14 and 15-21 days respectively. (Fig.1).

DISCUSSION

Study conducted by Natarajan G et al11 reported that if caffeine was used for the treatment of apnea in prematurity there was no need of additional monitoring for serum concentration of nitrogen, creatinine and enzyme level which is necessary to monitor in any other drug used for apnea in prematurity. He also reported that plasma concentrations of caffeine increased on high doses.

Maria S, et al12 also conducted a study on comparison of caffeine and Theophylline when used in apnea of prematurity and reported that caffeine is superior to Theophylline when used early stages of prematurity infants < 33 weeks. He also reported that both regimens not required extra monitoring in three weeks of prematurity. This study is comparable with our study.

In 2015 Jeong Ket al13conducted a study and reported superiority of caffeine over theophylline in short term treatment of apnea in prematurity. He also reported that caffeine is effective and easy to administer. Shivakumar M et al14 compared caffeine with aminophylline and reported caffeine and aminophylline are equally effective.

In a study conducted by Mohammed Set al15 reported that caffeine can cause extubation failure in preterm ventilator patients and reduce the incidence of apnea in prematurity with minimum major side effects. Another study by Marcus CL, et al16 reported similar findings of apnea reduction.

Henderson-Smart DJ, et al17 reported caffeine and theophylline being equally effective for treatment of apnea but caffeine has more advantages over Theophylline. On other hand Theophylline have greater incidences of toxicity. These findings are also similar to our findings.

Steer PA, et al18 and Markantonis SL19 also reported similar findings and these studies are also comparable with our findings. According to this study caffeine is more safe and effective than any other drug used for apnea and prematurity.

CONCLUSION

Results of our study revealed that caffeine is more effective than Theophylline in treatment of apnea of prematurity.

REFERENCES

1. Vliegenthart R, Hove C, Onland W, Anton H. Doxapram Treatment for Apnea of Prematurity: A Systematic Review. Neonatol. 2016;111(2):162-171. doi: 10.1159/000448941.

2. Kua K, Huey S. Systematic review and meta-analysis of clinical outcomes of early caffeine therapy in preterm neonates. Br J Clin Pharmacol. 2017;83(1):180-191. doi:10.1111/bcp.13089

3. Abdel-Hady H, Nasef N, Shabaan A, Nour I. Caffeine therapy in preterm infants. World J Clin Pediatr. 2015;4(4):81-93. doi:10.5409/wjcp.v4.i4.81

4. Zhao J, Gonzalez F, Mucor D. Apnea of prematurity: from cause to treatment. Eur J Pediatr. 2011;170(9):1097-1105. doi:10.1007/s00431-011-1409-6

5. Schoen K, Yu T, Stockmann C, Spigarelli M, Sherwin C. Use of Methylxanthine Therapies for the Treatment and Prevention of Apnea of Prematurity. Paediatr Drugs. 2014;16(2):169-177. doi: 10.1007/s40272-013-0063-z.

6. Urquhart DS. Investigation and management of childhood sleep apnoea. Hippokratia. 2013;17(3):196-202.

7. Francart S, Allen M, Stegall-Zanation J. Apnea of Prematurity: Caffeine Dose Optimization. J Pediatr Pharmacol Ther. 2013;18(1):45-52. doi: 10.5863/1551-6776-18.1.45

8. Dobson N, Patel R, Smith B, Kuehn D, Clark J, Laughon M, et al. Trends in Caffeine Use and Association between Clinical Outcomes and Timing of Therapy in Very-Low-Birth-Weight Infants. J Pediatr. 2014;164(5):992-998. doi: 10.1016/j.jpeds.2013.12.025

9. Shreshta B, Jawa G. Caffeine citrate - Is it a silver bullet in neonatology? Pediatr Neonatol. 2017;58(5):391-397. doi:10.1016/j.pedneo.2016.10.003

10. Lista G, Fabbri L, Polackova R, Papagaroufalis K, Saenz P, Ferrari F. The Real-World Routine Use of Caffeine Citrate in Preterm Infants: A European Post authorization Safety Study. Neonatol. 2016;109:221-227. doi:10.1159/000442813

11. Natarajan G, Botica ML, Thomas R, Aranda JV. Therapeutic drug monitoring for caffeine in preterm neonates: an unnecessary exercise? Pediatr. 2007;119:936-940. doi:10.1542/peds.2006-2986

12. Maria S, Flora B, Sophia LM. Caffeine versus theophylline for apnea of prematurity: A randomised controlled trial. J Pediatr Child Health. 2009;45:587-592. doi: 10.1111/j.1440-1754.2009.01570.x

13. Jeong K, Kim HS, Song ES, Choi YY. Comparison between Caffeine and Theophylline Therapy for Apnea of Prematurity. Neonatal Med. 2015;22(1):14-20. doi: 10.5385/nm.2015.22.1.14

14. Shivakumar M, Jayashree P, Najih M, Lewis LES, Bhat Y R, Kamath A, et al. Comparative Efficacy and Safety of Caffeine and Aminophylline for Apnea of Prematurity in Preterm (a$?34 weeks) Neonates: A randomized controlled trial. Ind Pediatr. 2017;54(4):279-283. doi: 10.22038/ijn.2017.23031.1281.

15. Mohammed S, Nour I, Shabaan AE, Shouman B, Abdel-Hady H, Nasef N. High versus low-dose caffeine for apnea of prematurity: a randomized controlled trial. Eur J Pediatr. 2015;174(7):949-956. doi:10.1007/s00431-015-2494-8

16. Marcus CL, Meltzer LJ, Roberts RS. Long-Term Effects of Caffeine Therapy for Apnea of Prematurity on Sleep at School Age. Am J Respir Crit Care Med. 2014;190(7):791-799. doi: 10.1164/rccm.201406-1092OC.

17. Henderson-Smart DJ, Steer PA. Caffeine versus theophylline for apnea in preterm infants. Cochrane Database Syst Rev. 2010;(1):CD000273. doi: 10.1002/14651858.CD000273.pub2.

18. Steer PA. Caffeine versus theophylline for apnea in preterm infants. Cochrane Database Syst Rev. 2000;(2):CD000273. doi:10.1002/14651858.CD000273

19. Skouroliakou M, Bacopoulou F, Markantonis SL. Caffeine versus theophylline for apnea of prematurity: A randomised controlled trial. J Paediatr Child Health. 2009;45(10):587-592. doi:10.1111/j.1440-1754.2009.01570.x
COPYRIGHT 2019 Knowledge Bylanes
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Pakistan Journal of Medical Sciences
Date:Feb 28, 2019
Words:2698
Previous Article:Clinical characteristics and long-term prognosis of spontaneous coronary artery dissection: A single-center Chinese experience.
Next Article:The role of Endocan as a Prognostic Biomarker in community-acquired pneumonia.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters